BCAL Diagnostics
- Company typePublic
- Founded2010
- HeadquartersSydney, Australia
- Headcount11–50
- GTM typeB2C
- OfferingServices
BCAL Diagnostics firmographics
Firmographics- Name
- BCAL Diagnostics
- Legal name
- BCAL Diagnostics Limited
- Website
- https://bcaldiagnostics.com
- Company type
- Public
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
BCAL Diagnostics industry classification
Industry- Product category
- Cancer Diagnostics
- NAICS
- Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
- akta.pro secondary industries
- Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Breast Oncology (HLAKAFAJ), Proteomics & Mass Spectrometry Services (HLAGANAB), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI)
Keywords
Where BCAL Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Sydney
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
BCAL Diagnostics business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Direct Diagnostic Test Sales: BCAL sells its diagnostic blood tests directly to patients through healthcare professional consultations. Tests are ordered by doctors and performed at approved blood collection centres. Revenue is generated on a per-test basis.
- Commercial Partnership Revenue: Revenue generated through commercial partnerships with pathology networks (Sonic Healthcare, Healius) for distribution of Avantect tests. Tests are priced at $1,495 per test or $1,995 for combined pancreatic and ovarian testing.
- BREASTEST plus Test Sales: First commercial product generating revenue at $300 per test, payable by patients at time of collection. Not currently covered by Medicare or private health insurance.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | BREASTEST plus single test |
| Unit Pricing | Pay-as-you-go | Avantect single cancer test |
| Unit Pricing | Pay-as-you-go | Avantect combined test |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels6 records
BCAL Diagnostics product offering
Product offeringCore offering
BCAL Diagnostics develops and performs non-invasive blood-based diagnostic tests for cancer detection through its NATA-accredited laboratory in Sydney, Australia. Its flagship BREASTEST plus measures plasma lipid biomarkers using LC-MS/MS technology and a proprietary diagnostic algorithm to support breast cancer screening, particularly for women with dense breast tissue. The company also distributes the licensed Avantect epigenomics-based blood tests for early detection of pancreatic and ovarian cancer through pathology network partnerships.
Product overview
BCAL Diagnostics offers a portfolio of non-invasive blood tests for cancer detection. The core product is BREASTEST plus™, a lipidomic-based blood test using LC-MS/MS technology designed to complement mammography for breast cancer screening, particularly for women with dense breast tissue. The company has licensed Avantect® tests from ClearNote Health for pancreatic and ovarian cancer early detection, expanding beyond breast cancer. BREASTEST Monitor is under development for breast cancer recurrence monitoring. All tests are ordered through healthcare professionals and processed at BCAL's NATA-accredited commercial laboratory in Sydney.
Differentiator
Problem solved
Functional benefit
Brands
- BREASTEST plus™: First-in-class blood test designed to be used alongside standard mammogram in breast cancer screening, particularly for women with dense breast tissue.
- BREASTEST Monitor
- Avantect®
Products and services
- BREASTEST plus A first-in-class lipidomic blood test designed to be used alongside mammography in breast cancer screening, providing additional information for women with dense breasts to help rule out the presence of breast cancer. Uses Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) to measure lipid biomarkers in blood plasma and converts measurements to a test score via a proprietary diagnostic algorithm.
- BREASTEST Monitor A blood test to assist in evaluating women for local breast cancer recurrence after treatment. Demonstrated 91% sensitivity and 95% negative predictive value in clinical studies involving women aged 50 and above with previous breast cancer diagnosis.
- Avantect Pancreatic Cancer Test Early detection blood test for pancreatic cancer, licensed from ClearNote Health. Epigenomics-based test leveraging artificial intelligence and advanced genomic analysis. Priced at $1,495 per test.
- Avantect Ovarian Cancer Test Early detection blood test for ovarian cancer, licensed from ClearNote Health. Epigenomics-based test leveraging artificial intelligence and advanced genomic analysis. Priced at $1,495 per test or $1,995 for combined pancreatic and ovarian testing.
Quantifiable outcome
- 91% sensitivity in detecting breast cancer recurrence in clinical study of 450+ samples
- +2 more outcomes
Companies that use BCAL Diagnostics
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
BCAL Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
BCAL Diagnostics partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- Sonic HealthcarecorePartnership with Sonic Healthcare for commercial rollout of Avantect early detection blood tests for pancreatic and ovarian cancers. Tests available through Sonic Pathology collection centres across Australia.
- HealiuscorePartnership with Healius for nationwide availability of Avantect pancreatic and ovarian cancer detection testing through Healius Pathology locations.
- ClearNote Health Inc.coreExclusive licence partnership with US-based ClearNote Health Inc. providing access to Avantect pancreatic and ovarian cancer early detection blood tests across Australia and New Zealand. The epigenomics-based tests leverage artificial intelligence and advanced genomic analysis.
- Sonic Healthcare (Initial Partnership)coreInitial partnership with Sonic Healthcare for pathology collection centre access to support commercial rollout of diagnostic tests.
- Cancer Care AssociatesminorCommercial partnership with Cancer Care Associates for distribution of cancer detection testing services.
- PrecionminorUS Product Development Agreement with Precion for product development activities in the United States market.
- Pancare FoundationminorHealth economic evidence development collaboration with Pancare Foundation to support reimbursement discussions for pancreatic cancer tests.
- PankindminorHealth economic evidence collaboration with Pankind to support reimbursement discussions for pancreatic cancer testing.
Scale indicators9 records
Recent moves7 records
Expansion highlights7 records
BCAL Diagnostics competitors and assessment
Company assessmentDirect peers
- Guardant Health: Guardant Health is a leading US liquid biopsy company offering blood-based oncology diagnostics (Guardant360, Shield). Directly comparable as a blood-based cancer diagnostic company with proprietary assays and AI-driven algorithms.
- GRAIL: GRAIL develops the Galleri multi-cancer early-detection blood test, the most directly comparable liquid biopsy cancer screening product to BCAL's BREASTEST plus and planned multi-cancer test. Both target early-stage cancer detection via a single blood draw.
- Natera: Natera offers Signatera, a blood-based ctDNA test for cancer recurrence monitoring, directly analogous to BCAL's BREASTEST Monitor. Both target minimal residual disease and recurrence detection via proprietary blood assays.
- ANGLE plc: ANGLE plc has developed Parsortix, a liquid biopsy platform for capturing circulating tumour cells. Comparable as a UK-listed oncology diagnostics company developing blood-based cancer detection technologies.
- VolitionRx: VolitionRx develops Nu.Q blood-based cancer diagnostics using nucleosome quantification. Comparable as a small-cap blood-based cancer diagnostics company targeting multi-cancer detection with proprietary biomarker assays.
- Pacific Edge: Pacific Edge (NZX/ASX-listed) commercialises Cxbladder, a urine-based cancer diagnostic test. Highly comparable as a NZX/ASX-listed cancer diagnostics company with a similar early-commercialisation profile; BCAL board member David Darling was previously its CEO.
- Exact Sciences: Exact Sciences commercialises Cologuard and Oncotype DX cancer screening/diagnostic tests. Comparable as a publicly-listed cancer diagnostics company with reimbursed blood/stool-based screening products at scale.
Others
- Sonic Healthcare: Sonic Healthcare is a major Australian/global pathology operator that is both a distribution partner for BCAL's Avantect tests and a broader diagnostics incumbent. Included for completeness as a key channel partner and reference customer for Australian pathology scale.
Broad incumbents
- Quest Diagnostics: Quest Diagnostics is a major US clinical laboratory offering extensive cancer diagnostics including molecular and pathology testing. Comparable as a broad incumbent with significant cancer diagnostics infrastructure; BCAL board member Dr John Hurrell previously led development of 70+ molecular diagnostics tests at Quest's Focus Diagnostics subsidiary.
Emerging players
- Mainz Biomed: Mainz Biomed is an emerging molecular genetics diagnostics company developing ColoAlert and PancAlert - blood/stool-based cancer screening tests. Comparable as a small-cap early-stage cancer diagnostics company expanding its test portfolio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
BCAL Diagnostics social profiles
Digital presenceBCAL Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
BCAL Diagnostics leadership team
Management profileNumber of profiles
Profiles12 records
BCAL Diagnostics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BCAL Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BCAL Diagnostics
What does BCAL Diagnostics do?
BCAL Diagnostics develops and performs non-invasive blood-based diagnostic tests for cancer detection through its NATA-accredited laboratory in Sydney, Australia. Its flagship BREASTEST plus measures plasma lipid biomarkers using LC-MS/MS technology and a proprietary diagnostic algorithm to support breast cancer screening, particularly for women with dense breast tissue. The company also distributes the licensed Avantect epigenomics-based blood tests for early detection of pancreatic and ovarian cancer through pathology network partnerships.
Is BCAL Diagnostics a public or private company?
BCAL Diagnostics is a public company. It is classified as public and is currently operating.
When was BCAL Diagnostics founded?
BCAL Diagnostics was founded in 2010. It employs 11 to 50 people.
Where is BCAL Diagnostics based?
BCAL Diagnostics is headquartered in Sydney, Australia, in the Oceania region.
How does BCAL Diagnostics make money?
Three revenue lines are on record. Direct Diagnostic Test Sales are the primary driver. The others are commercial Partnership Revenue and BREASTEST plus Test Sales.
Who are BCAL Diagnostics's main competitors?
Direct peers on record are Guardant Health, GRAIL, Natera, ANGLE plc, VolitionRx, Pacific Edge and Exact Sciences. Sonic Healthcare is listed as an others. Quest Diagnostics is listed as a broad incumbent. Mainz Biomed is listed as an emerging player.
Does BCAL Diagnostics have an API?
No public API is recorded for BCAL Diagnostics.
What industry is BCAL Diagnostics in?
BCAL Diagnostics's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAALAN, Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays. Its NAICS code is 62151 and its SIC code is 2835.